Alector

Belkins
We are a biotech company based in San Francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as Alzheimer's Disease.

Related News

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

MEDICAL

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular | January 13, 2021

news image

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More

CELL AND GENE THERAPY

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

news image

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More

INDUSTRIAL IMPACT

Enteris BioPharma | May 04, 2021

news image

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

BioSpace | March 02, 2020

news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

MEDICAL

GT Molecular | January 13, 2021

news image

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More

CELL AND GENE THERAPY

Mekonos | November 24, 2020

news image

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More